Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

A new report from AARP Public Policy Institute found that the top 25 drugs prescribed under Medicare Part D have nearly ...

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal ...

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at UBS Group from a “sell” rating to a ...

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK875.00.

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

Hotter-than-expected jobs data and bond yields pressured stocks, resulting in weekly losses for all three indexes ...

Calling people "mentally ill" based on their sexual identity and referring to women as "household objects" will now be allowed in the context of political discussions on social media giant Meta's ...